ZEB2: A Potential Drug Target Or Biomarker (G9839)

Target Name: ZEB2

NCBI ID: G9839

ZEB2

ZEB2: A Potential Drug Target Or Biomarker

ZEB2 (Zinc finger E-box binding homeobox 2, transcript variant 2) is a gene that has been identified as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. ZEB2 is a protein that is expressed in many different tissues and cells in the body, including brain, muscle, heart, and blood cells. It is a zinc finger gene, which means that it contains a zinc finger domain that is responsible for binding to certain proteins, including transcription factors.

The zinc finger domain is a unique feature that is found in many proteins that help them to interact with DNA. It consists of a nucleotide sequence that is repeated multiple times, which creates a stable association with the protein. This domain is thought to play a role in the regulation of gene expression, and it is believed to be involved in the development and progression of many different diseases.

One of the things that makes ZEB2 an interesting potential drug target is its involvement in the development and progression of cancer. Many studies have shown that high levels of ZEB2 are associated with the development of cancer, and that inhibiting its activity may be an effective way to treat this disease. For example, researchers have found that inhibiting the activity of ZEB2 can significantly reduce the growth of cancer cells in cell culture and animal models.

In addition to its potential as a cancer drug, ZEB2 is also being studied as a potential biomarker for the disease. Many researchers are interested in using ZEB2 as a diagnostic or predictive factor for cancer, because it is expressed in many different tissues and cells, and it is relatively stable over time. This makes it an attractive candidate for use as a biomarker, because it can be easily measured and detected in a variety of settings, such as blood samples or tissue samples.

Another potential application of ZEB2 as a drug target is its role in the development and progression of neurodegenerative diseases. Many of these diseases, such as Alzheimer's and Parkinson's, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. ZEB2 is thought to be involved in the regulation of the production and distribution of these tangles, and it is possible that inhibiting its activity may be an effective way to treat these diseases.

In addition to its potential as a drug or biomarker, ZEB2 is also of interest to researchers because of its unique structure and biology. ZEB2 is a member of a family of proteins that are known as zinc finger genes, and it is characterized by the presence of a zinc finger domain and a C-terminal region. This structure is thought to be unique, and it is likely to play a critical role in the function of the protein.

Overall, ZEB2 is an interesting gene that is being studied for its potential as a drug target or biomarker for a variety of diseases. Its involvement in the regulation of gene expression and its unique structure and biology make it an attractive candidate for further research. While more research is needed, the potential of ZEB2 as a drug or biomarker for cancer, neurodegenerative diseases, and other conditions is exciting and promising.

Protein Name: Zinc Finger E-box Binding Homeobox 2

Functions: Transcriptional inhibitor that binds to DNA sequence 5'-CACCT-3' in different promoters (PubMed:16061479, PubMed:20516212). Represses transcription of E-cadherin (PubMed:16061479). Represses expression of MEOX2 (PubMed:20516212)

The "ZEB2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZEB2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets